Brett D. M. Jones

发表

Association of Repetitive Transcranial Magnetic Stimulation Treatment With Subgenual Cingulate Hyperactivity in Patients With Major Depressive Disorder

P. Fitzgerald, R. Zomorrodi, D. Blumberger, 2019, JAMA network open.

Association of Repetitive Transcranial Magnetic Stimulation Treatment With Subgenual Cingulate Hyperactivity in Patients With Major Depressive Disorder

P. Fitzgerald, R. Zomorrodi, D. Blumberger, 2019, JAMA network open.

Relative effectiveness of augmentation treatments for treatment-resistant depression: a systematic review and network meta-analysis

A. Young, A. Carvalho, A. Cleare, 2020, International review of psychiatry.

Targeting Metabolic Dysfunction for the Treatment of Mood Disorders: Review of the Evidence

B. Mulsant, M. Husain, S. Kloiber, 2021, Life.

Boxing as an Intervention in Mental Health: A Scoping Review

Z. Daskalakis, Brett D. M. Jones, M. Husain, 2022, American journal of lifestyle medicine.

Repurposing Anti-inflammatory Agents for Mood Disorders: an Updated Review of Current Evidence

M. Husain, Brett D. M. Jones, Mary E. Kittur, 2022, Current Treatment Options in Psychiatry.

Astrocytes in the Neuropathology of Bipolar Disorder: Review of Current Evidence

M. Husain, Brett D. M. Jones, Nasia Dai, 2022, Brain sciences.

Repurposing Anti-inflammatory Agents for Mood Disorders: an Updated Review of Current Evidence

M. Husain, Brett D. M. Jones, Mariam Mahboob, 2022, Current Treatment Options in Psychiatry.

Tranquilizer/Anxiolytics: Benzodiazepines (Intermediate-Acting) – Alprazolam, Bromazepam, Clonazepam, Lorazepam

M. Husain, Brett D. M. Jones, 2021 .

Serial Measures of the Cortisol Awakening Response during Treatment for Depression in an Inpatient Setting

Brett D. M. Jones, 2013 .

Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence

Nelson B Rodrigues, R. McIntyre, J. Rosenblat, 2021, Psychiatry Research.

Inflammation as a treatment target in mood disorders: review

A. Young, B. Mulsant, A. Carvalho, 2020, BJPsych Open.

Metabolic function in patients with bipolar depression receiving anti-inflammatory agents: findings from the MINDCARE study, a multicentre, randomised controlled trial.

A. Young, B. Mulsant, J. Hodsoll, 2021, Journal of affective disorders.

The use of sequential pharmacotherapy for the treatment of acute major depression: a scoping review

B. Mulsant, M. Husain, Brett D. M. Jones, 2021, Expert opinion on pharmacotherapy.

A systematic review on the effectiveness of dialectical behavior therapy for improving mood symptoms in bipolar disorders

B. Mulsant, A. Ortiz, M. Husain, 2023, International Journal of Bipolar Disorders.

High reactivity of the cortisol awakening response predicts positive treatment outcome in heterogeneous depressed patients completing an alternate milieu inpatient program.

A. Ravindran, R. Levitan, S. Matthews, 2015, General hospital psychiatry.

Magnitude of the Placebo Response Across Treatment Modalities Used for Treatment-Resistant Depression in Adults

B. Mulsant, A. Brunoni, A. Brunoni, 2021, JAMA network open.

A cross-sectional study of cognitive performance in bipolar disorder across the lifespan: the cog-BD project

B. Mulsant, M. Butters, A. Voineskos, 2022, Psychological Medicine.

Protocol for a systematic review and meta-analysis of the placebo response in treatment-resistant depression: comparison of multiple treatment modalities

Z. Daskalakis, A. Brunoni, A. Brunoni, 2021, BMJ Open.

The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine.

Nelson B Rodrigues, R. McIntyre, J. Rosenblat, 2021, Journal of affective disorders.

Brief App-Based Cognitive Behavioral Therapy for Anxiety Symptoms in Psychiatric Inpatients: Feasibility Randomized Controlled Trial

B. Mulsant, D. Blumberger, M. Husain, 2022, JMIR Formative Research.

Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial

B. Mulsant, W. Wang, D. Blumberger, 2023, BJPsych Open.

Efficacy and acceptability of adjunctive psychological and pharmacological interventions for treatment-resistant depression: protocol for a systematic review and network meta-analysis

A. Young, A. Carvalho, B. Carter, 2019, BMJ Open.

Tranquilizer/Anxiolytics: Buspirone

M. Husain, Brett D. M. Jones, 2021 .

Treatment outcomes in major depressive disorder in patients with comorbid alcohol use disorder: A STAR*D analysis.

D. Blumberger, Z. Daskalakis, M. Sloan, 2023, Journal of affective disorders.

Associations between peripheral inflammation and clinical phenotypes of bipolar depression in a lower-middle income country

B. Mulsant, J. Hodsoll, A. Ortiz, 2023, CNS Spectrums.

Predictors of change in suicidal ideation across treatment phases of major depressive disorder: analysis of the STAR*D data

B. Mulsant, D. Blumberger, Z. Daskalakis, 2021, Neuropsychopharmacology.

Attachment style at discharge predicts depression status four months following a 28-day alternate-milieu inpatient program.

A. Ravindran, R. Levitan, Brett D. M. Jones, 2014, Asian journal of psychiatry.

Efficacy and acceptability of adjunctive psychological and pharmacological interventions for treatment-resistant depression: protocol for a systematic review and network meta-analysis

A. Young, A. Carvalho, B. Carter, 2019, BMJ Open.

Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders.

B. Mulsant, D. Blumberger, J. Rosenblat, 2023, Journal of psychoactive drugs.